In a report released today, Suji Jeong from Jefferies maintained a Buy rating on Reneo Pharmaceuticals (RPHM – Research Report), with a price target of $17.00. The company’s shares closed yesterday at $2.71.
According to TipRanks, Jeong is an analyst with an average return of -24.3% and a 14.29% success rate. Jeong covers the Healthcare sector, focusing on stocks such as uniQure, Paratek Pharmaceuticals, and Verona Pharma.
Reneo Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $22.50.
See today’s best-performing stocks on TipRanks >>
RPHM market cap is currently $63.53M and has a P/E ratio of -1.35.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
